{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:00:30Z","timestamp":1765882830979,"version":"3.48.0"},"reference-count":17,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["219546"],"award-info":[{"award-number":["219546"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,3,20]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The HOLA study is a 12-month randomised, hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study including virologically suppressed people living with HIV (PWH). HOLA, which started in September 2023, evaluates acceptability, appropriateness, feasibility and satisfaction of out-of-hospital administration of cabotegravir and rilpivirine long-acting (CAB+RPV LA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 110 PWH who are already under treatment with CAB+RPV LA or switch their antiretroviral therapy to CAB+RPV LA will be recruited from two main hospitals in Barcelona (Germans Trias I Pujol and Vall d\u2019Hebr\u00f3n) and Costa del Sol Hospital, in Marbella. The patients will be randomised 1:1 into a hospital group (administration of CAB+RPV LA in the hospital) and the outpatient group (out-of-hospital administration), including community or primary care centres. The main objectives of the study are to compare the acceptability at month 12 of the administration of CAB+RPV LA in and out-of-hospital centres from the perspective of patients, and assess and compare the safety and tolerability of CAB+RPV LA. The study takes place at nine clinical units in Catalonia and Andalusia (three tertiary hospitals (recruiting centres), one community centre, one sexually transmitted infection clinic and four primary care centres).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The current publication refers to V.3.0 of the protocol, with issue date 14 April 2024, as approved by the Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n con medicamentos del Hospital Universitari Germans Trias i Pujol (approval number AC-23-042-HGT-CEIM). The clinical trial will be conducted according to the principles of the Declaration of Helsinki, Fortaleza, Brazil, October 2013. This study will be conducted according to Spanish regulations regarding clinical trials (Royal Decree 1090\/2015) and biomedical investigations (Organic Law 14\/2007 of biomedical investigation and the Royal Decree 1716\/2011), and the Clinical Trial Regulation (Regulation EU No 536\/2014). Confidentiality requirements will follow the required Data Protection legislation. Enrolment completion in the study is expected by the end of May 2024, with an end of study expected in May 2025. Results emerging from this study will be reported in HIV national and international meetings as well as published in international journals with a high impact factor. If the outcome is deemed positive, we will also develop and propose policy guidelines for the integration of the administration of CAB+RPV LA in alternative outpatient facilities into the standard of care in the HIV care pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06185452\">NCT06185452<\/jats:ext-link>\n                      \/EUCT number: 2023-503963-41-00.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088514","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T23:25:16Z","timestamp":1744327516000},"page":"e088514","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)\u2014a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06185452","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06185452","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06643897","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04399551","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eugenia","family":"Negredo","sequence":"first","affiliation":[{"name":"Fundacio Lluita contra les Infeccions, Badalona, Spain"},{"name":"UVic-UCC, Vic, Spain"},{"name":"Medicine, Autonomous University of Barcelona, Barcelona, Spain"},{"name":"CIBERINFEC, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7377-7693","authenticated-orcid":false,"given":"Diana","family":"Hern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Fundacio Lluita contra les Infeccions, Badalona, Spain"},{"name":"Medicine, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"\u00c1lvarez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Centre de Salut Internacional i Malalties Transmissibles Drassanes - Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"additional","affiliation":[{"name":"Medicine, Autonomous University of Barcelona, Barcelona, Spain"},{"name":"Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c0ngel","family":"Rivero","sequence":"additional","affiliation":[{"name":"Fundacio Lluita contra les Infeccions, Badalona, Spain"},{"name":"Projecte dels NOMS-Hispanosida, BCN CheckPoint, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Jusmet","sequence":"additional","affiliation":[{"name":"Centre de Atenci\u00f3 Prim\u00e0ria Dr. Robert, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Cuerda Palomo","sequence":"additional","affiliation":[{"name":"Centro de Salud de San Luis de Sabinillas, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Bel\u00e9n","family":"Flores de la Cruz","sequence":"additional","affiliation":[{"name":"Centro de Salud de San Pedro de Alc\u00e1ntara, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Pav\u00f3n","sequence":"additional","affiliation":[{"name":"Centro de Salud Leganitos, Marbella, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Llavero","sequence":"additional","affiliation":[{"name":"Pharmacy, University Hospital Germans Trias i Pujol, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Campany","sequence":"additional","affiliation":[{"name":"Pharmacy, Vall d'Hebron University Hospital, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Faus","sequence":"additional","affiliation":[{"name":"Pharmacy, Hospital Costa del Sol, Marbella, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Broto-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Centre de Salut Internacional i Malalties Transmissibles Drassanes - Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Bail\u00f3n","sequence":"additional","affiliation":[{"name":"Fundacio Lluita contra les Infeccions, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e1maris","family":"Aguilar","sequence":"additional","affiliation":[{"name":"Hospital Costa del Sol, Marbella, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Hospital Costa del Sol, Marbella, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Miranda","sequence":"additional","affiliation":[{"name":"Fundacio Lluita contra les Infeccions, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Puig","sequence":"additional","affiliation":[{"name":"Fundacio Lluita contra les Infeccions, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rovira","sequence":"additional","affiliation":[{"name":"Fundacio Lluita contra les Infeccions, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e1n","family":"Olalla","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Costa del Sol, Marbella, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"unstructured":"UNAIDS . About UNAIDS. Available: https:\/\/www.unaids.org\/en\/whoweare\/about [Accessed 04 Feb 2025].","key":"2025121602561450000_15.4.e088514.1"},{"key":"2025121602561450000_15.4.e088514.2","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1038\/s41598-023-44768-2","article-title":"Investigating coping and stigma in people living with HIV through narrative medicine in the Italian multicentre non-interventional study DIAMANTE","volume":"13","author":"Antinori","year":"2023","journal-title":"Sci Rep"},{"key":"2025121602561450000_15.4.e088514.3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.eimc.2022.07.012","article-title":"Achieving the UNAIDS goals by 2030 in people living with HIV: A simulation model to support the prioritization of health care interventions","volume":"41","author":"Coll","year":"2023","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"2025121602561450000_15.4.e088514.4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40271-023-00641-y","article-title":"Preferences of People Living with HIV for Long-Acting Antiretroviral Treatment in Germany: Evidence from a Discrete Choice Experiment","volume":"16","author":"Emmert","year":"2023","journal-title":"Patient"},{"key":"2025121602561450000_15.4.e088514.5","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s40121-023-00840-y","article-title":"Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain","volume":"12","author":"Moreno","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2025121602561450000_15.4.e088514.6","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2025121602561450000_15.4.e088514.7","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"doi-asserted-by":"publisher","key":"2025121602561450000_15.4.e088514.8","DOI":"10.1056\/NEJMoa1904398"},{"doi-asserted-by":"publisher","key":"2025121602561450000_15.4.e088514.9","DOI":"10.1007\/s10461-020-03055-1"},{"doi-asserted-by":"publisher","key":"2025121602561450000_15.4.e088514.10","DOI":"10.1007\/s10488-010-0319-7"},{"doi-asserted-by":"publisher","key":"2025121602561450000_15.4.e088514.11","DOI":"10.1186\/s13012-017-0635-3"},{"key":"2025121602561450000_15.4.e088514.12","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26243","article-title":"Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations","volume":"27","author":"Gutner","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2025121602561450000_15.4.e088514.13","doi-asserted-by":"crossref","DOI":"10.1177\/23259582241269837","article-title":"Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study","volume":"23","author":"Gutner","year":"2024","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2025121602561450000_15.4.e088514.14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1023\/A:1013050904635","article-title":"Validation of the HIV treatment satisfaction questionnaire (HIVTSQ)","volume":"10","author":"Woodcock","year":"2001","journal-title":"Qual Life Res"},{"key":"2025121602561450000_15.4.e088514.15","doi-asserted-by":"crossref","first-page":"681058","DOI":"10.3389\/fpsyg.2021.681058","article-title":"Development of a Clinic Screening Tool to Identify Burdensome Health-Related Issues Affecting People Living With HIV in Spain","volume":"12","author":"Fuster-RuizdeApodaca","year":"2021","journal-title":"Front Psychol"},{"key":"2025121602561450000_15.4.e088514.16","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1007\/s12325-023-02656-1","article-title":"Psychometric Validation of the Perception of Injection (PIN) Questionnaire Using Data From Two Phase III, Open-Label, Active-Controlled, Non-Inferiority Studies in People Living With HIV","volume":"40","author":"Chounta","year":"2023","journal-title":"Adv Ther"},{"doi-asserted-by":"crossref","unstructured":"De Wit S , Rami A , Bonnet F , et al . 1584. CARISEL A Hybrid III Implementation Effectiveness Study of implementation of Cabotegravir plus Rilpivirine Long Acting (CAB+RPV LA) in EU Health Care Settings Key Clinical and Implementation Outcomes by Implementation Arm. Open Forum Infect Dis 2022;9. doi:10.1093\/ofid\/ofac492.107","key":"2025121602561450000_15.4.e088514.17","DOI":"10.1093\/ofid\/ofac492.107"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:56:27Z","timestamp":1765882587000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,10]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjopen-2024-088514"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088514","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}